John Pollard’s Post

Today, we are proud to lauch a new product at Hematology TA in Japan. Thank you to all investigators, patients, and colleagues who made this significant achievement possible in Japan. Now is our time; let’s “Go Beyond, for Patients, as One Dream Team!” Vasilisa Sazonov, PhD, Santiago Correa, Kay Moeller-Heske, PhD, Jonathan Van Garsse, Timothy Stiefel, Daisuke Yamashita, Thomas Holbro, KEIICHIRO SETSUNE, Hanae Ishioka, Masashi Umeda

Excited to share my latest review article publication😍🕉️ Dive into the depths of knowledge as I explore groundbreaking insights in FUSED AND SUBSTITUTED PYRIMIDINE DERIVATIVES AS POTENT ANTI-CANCER AGENTS 📝 Finally I got my first article publication as a corresponding author ✨ #Reviewarticle #Publication

At the ongoing American Society of Clinical Oncology (ASCO) 2024 conference, Agenus presented a novel analysis from the Phase Ib trial of botensilimab in combination with balstilimab (BOT/BAL) in relapsed/refractory microsatellite stable colorectal cancer (r/r MSS CRC) with no active liver metastases (NLM). Botensilimab is a multifunctional Fc-enhanced anti–CTLA–4 agent that has been shown to enhance T-cell priming, expansion, and memory, as well as increase the frequency of antigen-presenting cells and deplete regulatory T cells. Get Ahead with Expert Insights and Full Analysis through DelveInsight Business Research LLP's Exclusive ASCO 2024 Coverage! https://lnkd.in/guj-UxfA #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

The American Society of Clinical Oncology (ASCO) 2024 presentation showcased Cue Biopharma's Phase I trial of its leading interleukin 2 (IL-2)-based biologic, CUE-102, targeting Wilms’ Tumor 1 positive recurrent or metastatic cancers. CUE-102 has the potential to significantly alter the treatment landscape for patients with WT1-positive cancers by offering higher efficacy and lower toxicity compared to currently available treatments. Experience Expert Insights and Comprehensive Analysis with DelveInsight Business Research LLP's Special ASCO 2024 Coverage! https://lnkd.in/gs_rdz_j #ASCO24 #CancerTreatment #ASCO2024 #LungCancer #NSCLC #mCRPC #PharmaInnovation #MedicalResearch #OncologyAdvancements #ClinicalOncology #Pharmaceuticals #HealthcareConference #CancerResearch #ClinicalPractice #MedicalBreakthroughs #CancerCare #PharmaLeaders

In January 2024, Slamon et al. published the final overall survival (OS) analysis for the PALMOA-2 trial of first-line non-steroidal aromatase inhibitor (NSAI) and palbociclib. The results confirm what had been reported for a few years: palbociclib does not confer a statistically significant OS benefit over placebo. Because of these data, is this the end of palbociclib in the advanced setting? Read on here: https://lnkd.in/dSvPnyTz

Isothiocyanate from broccoli sprouts is known to be therapeutically valuable. Using the Raman spectroscopy facility in ADDReB of CVI, we showed that we could measure the Isothiocyanate level of human saliva and Cystic Fibrosis Transmembrane Regulator Function. @Carlos Milla @Paul L. Bollyky and Andrey Malkovskiy #cysticfibrosis#Isothiocyanate#Broccoli sprouts#Raman Spectroscopy#Cystic Fibrosis Transmembrane Regulator

Very interesting paper by the group of Jack Taunton in Nature Magazine. They used salicylaldehyde-based reactive groups to develop mutant-selective AKT1 (E17K) inhibitors. Key to selectivity is a very slow off-rate from the mutant due to neo-zinc chelation. https://lnkd.in/dHiGYw4v

Nice piece of work identifying a WEE1 degrader using a combinatorial library for CRBN molecular glue discovery ➡️ Library of compounds applied to an anti-proliferative phenotypic screen followed by whole-cell proteome profiling. ➡️ Identified WEE1/CK1α dual degraders ➡️ CryoEM structure of Cereblon/Ddb1-glue-Wee1 https://lnkd.in/eEmZU9qG

Check out our new review in Blood! Everything you ever wanted to know about heparan sulfates and heparan sulfate proteoglycans in hematopoiesis! https://lnkd.in/e7yABCwA

"Unlock the secrets of blood health with our Clinical Research Hematology Laboratory Course! Dive into the science of blood disorders, gain hands-on experience in advanced laboratory techniques, and learn from experts in the field. Join us on this journey to enhance patient outcomes through innovative hematological research!" 😊 🙂 🙂